DK2219647T3 - Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-HT3- og 5-HT1A-aktivitet - Google Patents

Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-HT3- og 5-HT1A-aktivitet

Info

Publication number
DK2219647T3
DK2219647T3 DK08850935.1T DK08850935T DK2219647T3 DK 2219647 T3 DK2219647 T3 DK 2219647T3 DK 08850935 T DK08850935 T DK 08850935T DK 2219647 T3 DK2219647 T3 DK 2219647T3
Authority
DK
Denmark
Prior art keywords
compounds
therapeutic uses
ht1a activity
sert
combined
Prior art date
Application number
DK08850935.1T
Other languages
English (en)
Other versions
DK2219647T4 (da
Inventor
Marianne Dragheim
Aneil Batra
Nicholas Moore
Jin Chon
Original Assignee
Lundbeck & Co As H
Takeda Pharmaceuticals North America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2219647(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H, Takeda Pharmaceuticals North America Inc filed Critical Lundbeck & Co As H
Publication of DK2219647T3 publication Critical patent/DK2219647T3/da
Application granted granted Critical
Publication of DK2219647T4 publication Critical patent/DK2219647T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK08850935.1T 2007-11-13 2008-11-12 Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet DK2219647T4 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98771007P 2007-11-13 2007-11-13
DKPA200701607 2007-11-13
US1372207P 2007-12-14 2007-12-14
DKPA200701788 2007-12-14
US9784008P 2008-09-17 2008-09-17
DKPA200801300 2008-09-17
PCT/DK2008/050271 WO2009062517A1 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (2)

Publication Number Publication Date
DK2219647T3 true DK2219647T3 (da) 2012-03-19
DK2219647T4 DK2219647T4 (da) 2020-09-28

Family

ID=40170671

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08850935.1T DK2219647T4 (da) 2007-11-13 2008-11-12 Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-ht3- og 5-ht1a-aktivitet
DK11193237.2T DK2431039T3 (da) 2007-11-13 2008-11-12 Terapeutisk anvendelse af forbindelser med kombineret sert-, 5-HT3 og 5-HT1A-aktivitet

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11193237.2T DK2431039T3 (da) 2007-11-13 2008-11-12 Terapeutisk anvendelse af forbindelser med kombineret sert-, 5-HT3 og 5-HT1A-aktivitet

Country Status (30)

Country Link
US (5) US9278096B2 (da)
EP (3) EP2431039B1 (da)
JP (2) JP5603244B2 (da)
KR (1) KR101536023B1 (da)
CN (1) CN102014908A (da)
AR (1) AR069260A1 (da)
AT (1) ATE537829T1 (da)
AU (1) AU2008323390B2 (da)
BR (1) BRPI0820474B8 (da)
CA (1) CA2705163C (da)
CL (1) CL2008003363A1 (da)
CO (1) CO6270322A2 (da)
CY (2) CY1112646T1 (da)
DK (2) DK2219647T4 (da)
EA (1) EA027783B1 (da)
ES (2) ES2379419T5 (da)
HR (2) HRP20120144T4 (da)
HU (1) HUE029588T2 (da)
IL (1) IL205466A (da)
LT (1) LT2431039T (da)
MX (1) MX2010004688A (da)
NZ (1) NZ585247A (da)
PL (2) PL2431039T3 (da)
PT (2) PT2219647E (da)
RS (2) RS55147B1 (da)
SG (1) SG10201405001XA (da)
SI (2) SI2431039T1 (da)
TW (1) TW200932233A (da)
WO (1) WO2009062517A1 (da)
ZA (1) ZA201003350B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
EA021321B1 (ru) 2009-08-24 2015-05-29 Х. Лундбекк А/С Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
DK2667715T3 (da) * 2011-01-27 2017-10-23 Neuren Pharmaceuticals Ltd Behandling af autismespektrumforstyrrelser ved anvendelse af glycyl-l-2-methylprolyl-l-glutaminsyre
WO2013012038A1 (ja) 2011-07-21 2013-01-24 学校法人名城大学 うつ病決定方法、セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
NZ708595A (en) * 2012-12-13 2019-06-28 H Lundbeck As Compositions comprising vortioxetine and donepezil
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
CN105339361A (zh) * 2013-05-31 2016-02-17 斯洛文尼亚莱柯制药股份有限公司 用于合成1-(2-((2，4-二甲基苯基)硫代)苯基)哌嗪的新方法
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
EP3082815B1 (en) * 2013-12-20 2018-10-03 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CN108348486A (zh) * 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
RU2018144248A (ru) 2016-07-01 2020-08-03 Х. Лундбекк А/С Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) * 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
JP2005513128A (ja) * 2001-12-20 2005-05-12 ハー・ルンドベック・アクチエゼルスカベット アリールオキシフェニル及びアリールスルファニルフェニル誘導体
SI1626720T1 (sl) 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
BRPI0713425A2 (pt) * 2006-06-16 2012-03-13 H. Lundbeck A/S composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
EA021321B1 (ru) 2009-08-24 2015-05-29 Х. Лундбекк А/С Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина

Also Published As

Publication number Publication date
SI2219647T2 (sl) 2020-11-30
BRPI0820474B8 (pt) 2021-05-25
PL2219647T3 (pl) 2012-07-31
US20180161321A1 (en) 2018-06-14
EP3115050A1 (en) 2017-01-11
HRP20120144T4 (hr) 2020-11-13
US20210093631A1 (en) 2021-04-01
ES2379419T3 (es) 2012-04-25
EP2219647B2 (en) 2020-07-29
US11628166B2 (en) 2023-04-18
EP2219647B1 (en) 2011-12-21
JP2011503125A (ja) 2011-01-27
CA2705163A1 (en) 2009-05-22
PT2219647E (pt) 2012-03-16
SI2219647T1 (sl) 2012-06-29
CA2705163C (en) 2013-02-12
EA201070598A1 (ru) 2010-10-29
US9744166B2 (en) 2017-08-29
US20160228430A1 (en) 2016-08-11
JP2014193891A (ja) 2014-10-09
NZ585247A (en) 2012-03-30
HRP20161121T1 (hr) 2017-01-27
SG10201405001XA (en) 2014-10-30
BRPI0820474A2 (pt) 2017-05-23
AU2008323390B2 (en) 2013-10-24
BRPI0820474B1 (pt) 2020-08-04
RS52256B2 (sr) 2020-11-30
KR20100099115A (ko) 2010-09-10
JP5841636B2 (ja) 2016-01-13
KR101536023B1 (ko) 2015-07-10
AU2008323390A1 (en) 2009-05-22
HUE029588T2 (en) 2017-03-28
CY1117978T1 (el) 2017-05-17
CY1112646T1 (el) 2016-02-10
HRP20120144T1 (en) 2012-04-30
IL205466A (en) 2014-06-30
EP2431039A1 (en) 2012-03-21
RS52256B (en) 2012-10-31
JP5603244B2 (ja) 2014-10-08
CN102014908A (zh) 2011-04-13
ZA201003350B (en) 2011-08-31
KR101536023B9 (ko) 2023-03-29
AR069260A1 (es) 2010-01-06
DK2431039T3 (da) 2016-09-26
SI2431039T1 (sl) 2017-01-31
CL2008003363A1 (es) 2009-06-05
LT2431039T (lt) 2016-10-10
EP2219647A1 (en) 2010-08-25
TW200932233A (en) 2009-08-01
DK2219647T4 (da) 2020-09-28
CO6270322A2 (es) 2011-04-20
US9278096B2 (en) 2016-03-08
PT2431039T (pt) 2016-09-29
ATE537829T1 (de) 2012-01-15
RS55147B1 (sr) 2016-12-30
EA027783B1 (ru) 2017-09-29
US20110201617A1 (en) 2011-08-18
WO2009062517A1 (en) 2009-05-22
IL205466A0 (en) 2010-12-30
PL2431039T3 (pl) 2016-12-30
ES2591110T3 (es) 2016-11-24
ES2379419T5 (es) 2021-05-04
EP2431039B1 (en) 2016-07-20
MX2010004688A (es) 2010-09-09
US20240082239A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
DK2219647T3 (da) Terapeutiske anvendelser af forbindelser med kombineret sert-, 5-HT3- og 5-HT1A-aktivitet
SMT201600203B (it) Enantiomeri di composti spiro-ossindolici e loro usi come agenti terapeutici
DK2191831T3 (da) Modificering af pirfenidon-behandling for patienter med atypisk leverfunktion
DK2117523T3 (da) Inhibitorer af AKT-aktivitet
DK2250161T3 (da) Forbindelser med CRTH2-antagonistaktivitet
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
BR112013013790A2 (pt) compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
DK1890684T3 (da) Behandling af søvn/vågenhedsforstyrrelser
DK2211901T3 (da) Vaccination med multiple clader af h5-influenza-a-virus
DK1898903T3 (da) Inhibitorer af Akt-aktivitet
DK2350416T4 (da) Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude
DK2222272T3 (da) Behandling af luftvejssygdom
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK3225251T3 (da) Modulering af pro-neurotrofinaktivitet
DK2848610T3 (da) Hæmmere af kinaseaktivitet
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2346408T3 (da) Overvågning af fosterhjerteaktivitet
BR112012000735A2 (pt) "métodos, kits e conjuntos de compostos"
DK1776136T3 (da) Behandling af tilstande, der involverer demyelinisering
DK1981506T3 (da) Langtidsbehandling af HIV-infektion med TMC278
DK2411009T3 (da) Terapeutiske anvendelser af quinazolindionderivater
NO20091266L (no) Fremgangsmåter for administrering av langvarige hypoglykemiske midler
DK2146991T3 (da) Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
DK2246477T3 (da) Spunspæl med dobbelt t-form
DK2382215T3 (da) Derivater af 2-pyridin-2-yl-pyrazol-3(2h)-on, fremstilling og terapeutisk anvendelse heraf